Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 9/20 | 0.50 |
| ▸ | TLR7 | Q9NYK1 | 12/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723768 | 0.90 | TLR8 (0.48) | TLR8TLR7NUDT1KDM4EMAPT | |
| SCHEMBL6099996 | 0.90 | TLR8 (0.49) | TLR8TLR7NUDT1KDM4EMAPT | |
| SCHEMBL8326936 | 0.88 | TLR8 (0.53) | TLR8TLR7NUDT1KDM4EMAPT | |
| SCHEMBL4792464 | 0.87 | TLR7 (0.48) | TLR8TLR7NUDT1TSHRMEN1 | |
| SCHEMBL4308938 | 0.87 | TLR8 (0.47) | TLR8TLR7NUDT1KDM4EMAPT | |
| SCHEMBL4313003 | 0.86 | TLR8 (0.46) | TLR8TLR7NUDT1KDM4EMAPT | |
| SCHEMBL4319537 | 0.86 | TLR8 (0.48) | TLR8TLR7NUDT1KDM4EMAPT | |
| SCHEMBL3168166 | 0.86 | TLR8 (0.46) | TLR8TLR7NUDT1MAPTTSHR | |
| SCHEMBL5616927 | 0.85 | TLR8 (0.46) | TLR8TLR7NUDT1KDM4EMAPT | |
| SCHEMBL4792818 | 0.85 | TLR8 (0.44) | TLR8TLR7NUDT1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| EP-1653914-A4 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES CO (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1653914-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005018551-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR8 139/4885TLR7 69/4885NUDT1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.